English (UK)
中文版John Xu
We have a very unique T-cell engager Bi-specific antibody platform.
Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.
We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.
We are looking for China partners to codevelop the Bi-specific antibodies.
We are also raising the capital to set up the CHina subsidiary.
You can add my wechat: elite8800
Abpro
SVPDr. Zhenyan Yan
Genscript Biotech Corp
VP Corporate DevelopmentJoanne Yang
Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.
We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.
Syneos Health
Director, Business DevelopmentMrs. Joanne Yang
Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.
We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.
Syneos Health
Director, Business Development
Simon Yi
PhysioCue is digital health and therapy device development company, has developed a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.
PhysioCue
President
Ms. yu yu
RSD’s discovery platform encompasses biology, chemistry, structural biology and biophysics, in addition to the capabilities of newly acquired HD Biosciences (HDB), and is trusted by over 1,900 international clients, ranging from pharma and biotech to academia and non-profit institutions.
Responsive Web Design powered by 